# Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function

Study · id `cardio:ct-nct01825759` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01825759](<https://clinicaltrials.gov/study/NCT01825759>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01825759

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT01825759. Allocation not applicable; no masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2014-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT01825759, source copy `cardio:ctgov-nct01825759-2013-04-08`, retrieved 2026-10-26)
- Start date: 2013-01 (registry gives no type) (ClinicalTrials.gov record NCT01825759, source copy `cardio:ctgov-nct01825759-2013-04-08`, retrieved 2026-10-26)
- Primary completion: 2014-12 (anticipated) (ClinicalTrials.gov record NCT01825759, source copy `cardio:ctgov-nct01825759-2013-04-08`, retrieved 2026-10-26)
- Completion: 2014-12 (anticipated) (ClinicalTrials.gov record NCT01825759, source copy `cardio:ctgov-nct01825759-2013-04-08`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01825759, source copy `cardio:ctgov-nct01825759-2013-04-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01825759-2013-04-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function
- Condition: Coronary Heart Disease
- Condition: Essential Hypertension
- Intervention (Drug): danshen dripping pill
- Lead sponsor: West China Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: West China Hospital (`cardio:org-west-china-hospital`)

## Provenance

Content hash: 7f455543ef40a0074a6e08593298c55663f10002481be6290f3228619aad7efd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
